MPM BioVentures 2014, L.P. - 04 Sep 2026 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship
10%+ Owner
Issuer ticker
TRDA
Reported as of
04 Sep 2026
Net transaction value
-$1,905,768
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Sep 2026, 19:23:33 UTC
Prior SEC filing
03 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ansbert Gadicke

Key filing fact

MPM BioVentures 2014, L.P. filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 09 Sep 2026.

Key facts

  • This page summarizes MPM BioVentures 2014, L.P.'s Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
  • 3 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 09 Sep 2026, 19:23.

Change

  • Previous filing in this sequence was filed on 03 Sep 2026.
  • Current net transaction value: -$1,905,768.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (10)

CIK 0001609492 Primary reporting owner

MPM BioVentures 2014, L.P.

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke
Signature date
09 Sep 2026
CIK 0001134657

EVNIN LUKE

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Luke Evnin
Signature date
09 Sep 2026
CIK 0001134655

GADICKE ANSBERT

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Todd Foley
Signature date
09 Sep 2026
CIK 0001473930

Foley Todd

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.
Signature date
09 Sep 2026
CIK 0001609493

MPM BioVentures 2014 (B), L.P.

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC
Signature date
09 Sep 2026
CIK 0001609495

MPM Asset Management Investors BV2014 LLC

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC
Signature date
09 Sep 2026
CIK 0001765021

MPM BioVentures 2014 LLC

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.
Signature date
09 Sep 2026
CIK 0001765091

MPM BioVentures 2014 GP LLC

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC
Signature date
09 Sep 2026
CIK 0001729504

MPM BIOVENTURES 2018 (B), L.P.

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
Signature date
09 Sep 2026
CIK 0001734817

MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Relationship
10%+ Owner
Address
C/O MPM BIOIMPACT, 399 BOYLSTON STREET, SUITE 1100, BOSTON
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC
Signature date
09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$273,735
Shares
-38,500
Change %
-0.93%
Price
$7.11
Shares after
4,106,452
Date
04 Sep 2026
Ownership
See Footnote
Footnotes
F1, F2, F3, F4
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$1,426,425
Shares
-192,500
Change %
-4.7%
Price
$7.41
Shares after
3,913,952
Date
08 Sep 2026
Ownership
See Footnote
Footnotes
F4, F5, F6, F7
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
TRDA transaction

Common Stock

Sale

Transaction value
$205,608
Shares
-28,837
Change %
-0.74%
Price
$7.13
Shares after
3,885,115
Date
09 Sep 2026
Ownership
See Footnote
Footnotes
F4, F8, F9, F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

MPM BioVentures 2014, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 10 footnotes

Footnote F1

The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

Footnote F2

Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Footnote F3

The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

Footnote F4

Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Footnote F5

The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

Footnote F6

Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Footnote F7

The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

Footnote F8

The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

Footnote F9

Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Footnote F10

The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

SEC remarks

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .